• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    AzurRx BioPharma, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    9/10/21 4:05:20 PM ET
    $AZRX
    Major Pharmaceuticals
    Health Care
    Get the next $AZRX alert in real time by email
    azrx_8k.htm
    0001604191false--12-3100016041912021-09-102021-09-10iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): September 10, 2021

     

    AzurRx BioPharma, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

     

    001-37853

     

    46-4993860

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    777 Yamato Road, Suite 502

    Boca Raton, Florida

     

    33431

    (Address of principal executive offices)

     

    (Zip Code)

     

    Registrant’s telephone number, including area code: (561) 589-7020

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading Symbol(s)

     

    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

     

    AZRX

     

    Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

      

    Item 3.03 Material Modification to Rights of Security Holders.

     

    To the extent required by Item 3.03 of Form 8-K, the information regarding the Reverse Stock Split (as defined below) contained in Item 5.03 of this Current Report on Form 8-K is incorporated by reference herein.

     

    Item 5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    On September 10, 2021, AzurRx BioPharma, Inc. (the “Company” or “AzurRx”) announced that it intends to effect a reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common stock (the “Common Stock”) at a ratio of 1 post-split share for every 10 pre-split shares. AzurRx’s Common Stock will continue to be traded on the NASDAQ Capital Market under the symbol AZRX and will begin trading on a split-adjusted basis when the market opens on Monday, September 13, 2021, under a new CUSIP number, 05502L204.

     

    At a special meeting of stockholders held on February 24, 2021, AzurRx’s stockholders granted the Company’s Board of Directors the discretion to effect a reverse stock split of AzurRx’s Common Stock through an amendment (the “Amendment”) to its Certificate of Incorporation at a ratio of not less than 1-for-5 and not more than 1-for-10, such ratio to be determined by the Company’s Board of Directors.

     

    On September 10, 2021, the Company filed the Amendment for the Reverse Stock Split with the Secretary of State of the State of Delaware, and the Reverse Stock Split will become effective in accordance with the terms of the Amendment at 12:01 AM Eastern Time on September 13, 2021 (the “Effective Time”).

     

    At the Effective Time, every ten shares of AzurRx’s issued and outstanding Common Stock will be converted automatically into one issued and outstanding share of Common Stock, with a corresponding 1-for-10 reduction in the number of authorized shares of Common Stock, but without any change in the par value per share. Stockholders holding shares through a brokerage account will have their shares automatically adjusted to reflect the 1-for-10 reverse stock split. It is not necessary for stockholders holding shares of the Common Stock in certificated form to exchange their existing stock certificates for new stock certificates of the Company in connection with the reverse stock split, although stockholders may do so if they wish.

     

    The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s equity, except to the extent that the reverse stock split would result in a stockholder owning a fractional share. No fractional shares will be issued in connection with the reverse split. Stockholders who would otherwise be entitled to receive a fractional share will instead receive a cash payment based on the closing price of the Common Stock as reported on Nasdaq on September 10, 2021. The reverse stock split will reduce the number of shares of Common Stock outstanding from approximately 93 million shares to approximately 9.3 million shares. Proportional adjustments will be made to the number of shares of Common Stock issuable upon exercise or conversion of AzurRx’s equity awards, convertible preferred stock and warrants, as well as the applicable exercise price. Stockholders with shares in brokerage accounts should direct any questions concerning the reverse stock split to their broker; all other stockholders may direct questions to the Company’s transfer agent, Colonial Stock Transfer, at 801-355-5740.

     

    The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated by reference herein.

     

    Item 7.01 Regulation FD Disclosure.

     

    On September 10, 2021, the Company issued a press release announcing the Reverse Stock Split, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d)

    Exhibit No.

     

    Description

     

    3.1

     

    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of AzurRx BioPharma, Inc., dated September 10, 2021.

     

    99.1

     

    Press Release Announcing the Reverse Stock Split, dated September 10, 2021.

     

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

    2

     

        

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    AzurRx BioPharma, Inc.

     

     

     

     

    September 10, 2021

    By:

    /s/ Daniel Schneiderman

     

    Name:

    Daniel Schneiderman

     

     

    Title:

    Chief Financial Officer

     

     

     

    3

     

    Get the next $AZRX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AZRX

    DatePrice TargetRatingAnalyst
    8/2/2021$2.50 → $2.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AZRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on AzurRx BioPharma with a new price target

      HC Wainwright & Co. reiterated coverage of AzurRx BioPharma with a rating of Buy and set a new price target of $2.00 from $2.50 previously

      8/2/21 6:16:37 AM ET
      $AZRX
      Major Pharmaceuticals
      Health Care
    • Roth Capital reiterated coverage on AzurRx BioPharma with a new price target

      Roth Capital reiterated coverage of AzurRx BioPharma with a rating of Buy and set a new price target of $5.00 from $7.00 previously

      4/1/21 9:17:16 AM ET
      $AZRX
      Major Pharmaceuticals
      Health Care
    • HC Wainwright & Co. reiterated coverage on AzurRx BioPharma with a new price target

      HC Wainwright & Co. reiterated coverage of AzurRx BioPharma with a rating of Buy and set a new price target of $2.50 from $3.50 previously

      4/1/21 6:44:15 AM ET
      $AZRX
      Major Pharmaceuticals
      Health Care

    $AZRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Coelho Mary Theresa

      4 - AzurRx BioPharma, Inc. (0001604191) (Issuer)

      9/13/21 8:08:11 PM ET
      $AZRX
      Major Pharmaceuticals
      Health Care
    • SEC Form 3 filed by Coelho Mary Theresa

      3 - AzurRx BioPharma, Inc. (0001604191) (Issuer)

      8/17/21 4:46:12 PM ET
      $AZRX
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Pennington James

      4 - AzurRx BioPharma, Inc. (0001604191) (Issuer)

      7/9/21 5:11:55 PM ET
      $AZRX
      Major Pharmaceuticals
      Health Care

    $AZRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today

      BOCA RATON, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("First Wave" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced that it will begin operating under its new corporate name, First Wave BioPharma, Inc., effective today upon the completion of certain filings with the Delaware Secretary of State. The Company's common shares will commence trading on the Nasdaq Capital Market under the new ticker symbol "FWBI" and CUSIP number (33749P101) at the market open on September 22, 2021. Formerly known as AzurRx BioPharma, Inc., the

      9/21/21 12:47:42 PM ET
      $AZRX
      Major Pharmaceuticals
      Health Care
    • AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma

      BOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today issued a letter to its shareholders from James Sapirstein, President, Chief Executive Officer and Chairman, regarding its recently announced merger with First Wave Bio, Inc. and adoption of the First Wave BioPharma name. The full text of the letter, which has also been posted to the Company's website, is as follows: Dear Shareholders, It is with great excitement and enthusiasm that I write to you, the shar

      9/14/21 7:30:00 AM ET
      $AZRX
      Major Pharmaceuticals
      Health Care
    • AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications

      AzurRx BioPharma to be renamed "First Wave BioPharma" and trade under new NASDAQ ticker symbol, "FWBI" Three IBD clinical indications, including ulcerative colitis and Crohn's disease, added to GI therapeutic pipeline with multiple near-term inflection points Conference call scheduled for today at 8:30 a.m. ET BOCA RATON, Fla., Sept. 13, 2021 (GLOBE NEWSWIRE) --  AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has entered a definitive agreement to acquire First Wave Bio, Inc. ("First Wave Bio") in a stock and cash transaction valued

      9/13/21 6:00:00 AM ET
      $AZRX
      Major Pharmaceuticals
      Health Care

    $AZRX
    SEC Filings

    See more
    • AzurRx BioPharma, Inc. filed SEC Form 8-K: Other Events

      8-K - First Wave BioPharma, Inc. (0001604191) (Filer)

      9/28/21 5:16:00 PM ET
      $AZRX
      Major Pharmaceuticals
      Health Care
    • AzurRx BioPharma, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - First Wave BioPharma, Inc. (0001604191) (Filer)

      9/21/21 4:38:38 PM ET
      $AZRX
      Major Pharmaceuticals
      Health Care
    • AzurRx BioPharma, Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - AzurRx BioPharma, Inc. (0001604191) (Filer)

      9/14/21 5:12:55 PM ET
      $AZRX
      Major Pharmaceuticals
      Health Care

    $AZRX
    Leadership Updates

    Live Leadership Updates

    See more
    • AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors

      BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted non-systemic, therapies for gastrointestinal (GI) diseases, today announced the appointment of Terry Coelho to its Board of Directors effective immediately. The appointment increases the size of AzurRx's Board to seven members. Ms. Coelho currently serves as the Executive Vice President and Chief Financial Officer at BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a commercial-stage specialty pharmaceutical company. During her more than 30-year career, Ms. Coelho has held numerous senior level financial an

      8/16/21 8:00:00 AM ET
      $AZRX
      $BCPC
      $BDSI
      Major Pharmaceuticals
      Health Care
      Major Chemicals
      Industrials
    • AzurRx BioPharma Appoints President and CEO James Sapirstein as New Chairman of the Board of Directors

      DELRAY BEACH, Fla., Feb. 24, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today the appointment of James Sapirstein, President and CEO, as chairman of the company’s board of directors, effective immediately. Mr. Sapirstein succeeds Mr. Edward J. Borkowski, who joined the AzurRx board in May 2015 and has served as chairman since April 2016. Mr. Borkowski will remain as lead independent director of the board of directors. “AzurRx is on the verge of several important inflection points, and

      2/24/21 7:00:00 AM ET
      $AZRX
      Major Pharmaceuticals
      Health Care

    $AZRX
    Financials

    Live finance-specific insights

    See more
    • AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications

      AzurRx BioPharma to be renamed "First Wave BioPharma" and trade under new NASDAQ ticker symbol, "FWBI" Three IBD clinical indications, including ulcerative colitis and Crohn's disease, added to GI therapeutic pipeline with multiple near-term inflection points Conference call scheduled for today at 8:30 a.m. ET BOCA RATON, Fla., Sept. 13, 2021 (GLOBE NEWSWIRE) --  AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has entered a definitive agreement to acquire First Wave Bio, Inc. ("First Wave Bio") in a stock and cash transaction valued

      9/13/21 6:00:00 AM ET
      $AZRX
      Major Pharmaceuticals
      Health Care

    $AZRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed

      SC 13D/A - AzurRx BioPharma, Inc. (0001604191) (Subject)

      2/10/21 9:54:48 AM ET
      $AZRX
      Major Pharmaceuticals
      Health Care